NCT00602576View on ClinicalTrials.gov

Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

169

Participants

Timeline

Start Date

January 1, 2005

Primary Completion Date

December 21, 2008

Study Completion Date

July 26, 2009

Conditions
Melanoma (Skin)
Interventions
DRUG

sorafenib tosylate

Given orally

DRUG

temozolomide

Given orally

Trial Locations (1)

19104-4283

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT00602576 - Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma | Biotech Hunter | Biotech Hunter